Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02281136 · ClinicalTrials.gov registry record · Phase 2

Maximal Use Systemic Exposure (MUSE) Study of Levulan Kerastick

A Phase 2 study, sponsored by DUSA Pharmaceuticals.

Completed
Registry status
Phase 2
Development phase
29
Enrollment target

NCT02281136: Completed Phase 2 study, sponsored by DUSA Pharmaceuticals.

NCT02281136 is a Phase 2 study that has completed, run by DUSA Pharmaceuticals. The registered enrollment target is 29 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (78% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02281136, a Phase 2 study, has completed, sponsored by DUSA Pharmaceuticals.

COMPLETED
Registry status
Phase 2
Development phase
29 participants
Enrollment target

Study Summary

The purpose of this study is to evaluate the potential for systemic exposure of aminolevulinic acid (ALA) when applied topically under occlusion, in a maximal use setting in patients with multiple actinic keratoses (AK) involving the upper extremities.

Primary Outcome

Maximum baseline corrected plasma concentration (Cmax) for ALA over the 24 hour sampling time period. Blood samples wiere taken before ALA application and at 15 and 30 minutes, 1, 2, 4, 8, 12, 16 and 24 hours following study medication application.

Interventions

  • DRUG Aminolevulinic Acid (ALA)
  • DEVICE BLU-U

Trial Details

FieldValue
Enrollment Target 29 participants
Start Date 2014-12
Est. Completion 2015-04
Phase Phase 2
DUSA Pharmaceuticals

10 total trials

What the finished NCT02281136 record still lists

NCT02281136 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (78% lower).

The record links to 0 conditions, and to 2 interventions - of which Aminolevulinic Acid (ALA) is the first listed.

NCT02281136 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02281136 about?

NCT02281136 is a clinical study titled "Maximal Use Systemic Exposure (MUSE) Study of Levulan Kerastick". The purpose of this study is to evaluate the potential for systemic exposure of aminolevulinic acid (ALA) when applied topically under occlusion, in a maximal use setting in patients with multiple actinic keratoses (AK) involving the upper extremities.

What is the current status of trial NCT02281136?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2014-12. Estimated completion is 2015-04.

What interventions are being tested in trial NCT02281136?

The interventions under investigation include: Aminolevulinic Acid (ALA) (DRUG), BLU-U (DEVICE).

Who is sponsoring clinical trial NCT02281136?

This trial is sponsored by DUSA Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02281136's enrollment target sits among peer trials

29 1669th of 2000 higher than 324 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02429557 · 29 participants · Phase 1

    Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure

  • NCT02568878 · 29 participants · Phase 3

    Creatine for Depressed Male and Female Methamphetamine Users

  • NCT03014401 · 29 participants · NA

    The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis

  • NCT03128996 · 29 participants · Phase 1

    Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02281136, the US trial registry maintained by the National Library of Medicine. NCT02281136 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.